DE2108726A1 - Lokalanasthetikum - Google Patents
LokalanasthetikumInfo
- Publication number
- DE2108726A1 DE2108726A1 DE19712108726 DE2108726A DE2108726A1 DE 2108726 A1 DE2108726 A1 DE 2108726A1 DE 19712108726 DE19712108726 DE 19712108726 DE 2108726 A DE2108726 A DE 2108726A DE 2108726 A1 DE2108726 A1 DE 2108726A1
- Authority
- DE
- Germany
- Prior art keywords
- local anesthetic
- pentazozine
- radical
- solution
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003589 local anesthetic agent Substances 0.000 title claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 20
- -1 alkyl radical Chemical class 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 19
- 229960004194 lidocaine Drugs 0.000 description 19
- 230000000202 analgesic effect Effects 0.000 description 18
- 206010037888 Rash pustular Diseases 0.000 description 15
- 208000029561 pustule Diseases 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 230000003444 anaesthetic effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 229960005015 local anesthetics Drugs 0.000 description 10
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 9
- 229930182837 (R)-adrenaline Natural products 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 9
- 229960005139 epinephrine Drugs 0.000 description 9
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 9
- 229960005301 pentazocine Drugs 0.000 description 8
- 230000007794 irritation Effects 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000003497 sciatic nerve Anatomy 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 210000000609 ganglia Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 2
- 125000006041 3-hexenyl group Chemical group 0.000 description 2
- 241000238017 Astacoidea Species 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004321 blink reflex Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- RMCDUNHIVVEEDD-UHFFFAOYSA-N methylcyclopropane Chemical compound [CH2]C1CC1 RMCDUNHIVVEEDD-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940066690 talwin Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/26—Benzomorphans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1421170A | 1970-02-24 | 1970-02-24 | |
| US42727173A | 1973-12-21 | 1973-12-21 | |
| US52132574 UST941017I4 (en) | 1970-02-24 | 1974-11-06 | Defensive publication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2108726A1 true DE2108726A1 (de) | 1971-09-09 |
Family
ID=27360042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712108726 Pending DE2108726A1 (de) | 1970-02-24 | 1971-02-24 | Lokalanasthetikum |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | UST941017I4 (enExample) |
| CA (1) | CA949879A (enExample) |
| DE (1) | DE2108726A1 (enExample) |
| FR (1) | FR2081535B1 (enExample) |
| GB (1) | GB1338172A (enExample) |
| NL (1) | NL7102372A (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4294840A (en) | 1979-02-12 | 1981-10-13 | Sterling Drug Inc. | Ketazocine anesthetic method of use |
| EP0692975A4 (en) * | 1993-04-08 | 2000-11-29 | Univ Queensland | ADMINISTRATION OF A VASO-ACTIVE AGENT AND A THERAPEUTIC AGENT |
-
1971
- 1971-02-17 CA CA105,626A patent/CA949879A/en not_active Expired
- 1971-02-23 NL NL7102372A patent/NL7102372A/xx unknown
- 1971-02-23 FR FR7106038A patent/FR2081535B1/fr not_active Expired
- 1971-02-24 DE DE19712108726 patent/DE2108726A1/de active Pending
- 1971-04-19 GB GB2242071A patent/GB1338172A/en not_active Expired
-
1974
- 1974-11-06 US US52132574 patent/UST941017I4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR2081535A1 (enExample) | 1971-12-03 |
| FR2081535B1 (enExample) | 1974-09-27 |
| UST941017I4 (en) | 1975-12-02 |
| NL7102372A (enExample) | 1971-08-26 |
| CA949879A (en) | 1974-06-25 |
| GB1338172A (en) | 1973-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3822792C2 (de) | Neue Verwendung von 5HT¶3¶-Antagonisten | |
| DE69231680T2 (de) | Neue verwendung von diphenylbutyl-piperazincarboxamiden zur behandlung von störungen im zusammenhang mit der verwendung giftiger stoffen | |
| AT390878B (de) | Verfahren zur herstellung einer pharmazeutischen zubereitung unter einsatz eines analgetischen und antiinflammatorischen nichtsteroiden wirkstoffes | |
| DE60100055T2 (de) | Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen | |
| DE3218761C2 (enExample) | ||
| DE69813839T2 (de) | Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz | |
| DE2062620A1 (de) | Optische Isomeren und Verfahren zu ihrer Spaltung | |
| DE3937340A1 (de) | Verfahren zur erzeugung von analgesie bei saeugern | |
| DE69209140T2 (de) | Verwendung Glycine/NMDA-Rezeptorliganden zur Herstellung eines Arzneimittels zur Behandlung von Drogenabhängigkeit und Entzugserscheinungen | |
| DE69328792T2 (de) | Behandlung von migräne | |
| DE69620027T2 (de) | Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs | |
| DE2350222A1 (de) | Pharmazeutische mittel, die ein 4-aryl-2-(3-pyridyl)-thiazol enthalten, und ihre anwendung | |
| DE1967073A1 (de) | Inosin-komplexverbindungen | |
| DE3445183A1 (de) | Proglumide enthaltende arzneimittel mit analgetischer wirkung | |
| DE69127285T2 (de) | Verwendung von verbindungen zur behandlung von altersbedingtem gedächtnisschwund und anderen kognitiven störungen | |
| DE69330638T2 (de) | Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem | |
| DE2108726A1 (de) | Lokalanasthetikum | |
| DE10163421A1 (de) | Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum | |
| DE1220967B (de) | Verfahren zur Herstellung hochwirksamer lokalanaesthetischer Zubereitungen | |
| DE2163055A1 (de) | Lokalanästhetisches Mittel | |
| DE69027577T2 (de) | Verwendung von Benzothiazepinen zur Herstellung von Arzneimitteln zur Behandlung von epileptischen Anfällen | |
| DE60004400T2 (de) | Kombinationsarzneimittel enthaltend trimebutin und ein opiatanalgetikum | |
| DE2754148A1 (de) | Substituierte aminoaethanole, verfahren zu ihrer herstellung und ihre verwendung als arzneistoffe | |
| DE3820817C2 (de) | Antileptikum | |
| DE2411019C2 (de) | Verwendung von 1-(4-(1-Pyrrolidinyl)-2-butynyl)-2-pyrrolidinon oder 1-(2-Oxo-1-pyrrolidin)-4-(1-pyrrolidin)-2-butyn zur Behandlung von Glaucoma |